1. Home
  2. GUT vs DCTH Comparison

GUT vs DCTH Comparison

Compare GUT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Utility Trust (The)

GUT

Gabelli Utility Trust (The)

HOLD

Current Price

$5.19

Market Cap

519.5M

Sector

Finance

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$14.42

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GUT
DCTH
Founded
1999
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.5M
578.4M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
GUT
DCTH
Price
$5.19
$14.42
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $24.00
AVG Volume (30 Days)
★ 281.8K
251.9K
Earning Date
01-01-0001
11-03-2026
Dividend Yield
★ 10.93%
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.61
Revenue Next Year
N/A
$24.27
P/E Ratio
★ N/A
$368.38
Revenue Growth
N/A
N/A
52 Week Low
$5.03
$8.12
52 Week High
$7.07
$17.42

Technical Indicators

Market Signals
Indicator
GUT
DCTH
Relative Strength Index (RSI) 27.11 39.08
Support Level N/A $14.26
Resistance Level $6.26 $16.51
Average True Range (ATR) 0.20 0.51
MACD -0.06 -0.06
Stochastic Oscillator 11.54 17.28

Price Performance

Historical Comparison
GUT
DCTH

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: